Her Majesty’s Revue and Customs (HMRC) have examined our business plan and cash flow forecasts of Drugs With A Difference Limited and given the company advanced assurance under their Enterprise Invest Scheme (EIS) to raise £3.45 million.

Any shares bought under this scheme have significant tax advantages and profits from shares kept for 3 years from the date of issue become net of (1) Income tax and (2) Capital Gains Tax.

We have recently filed 5 patent applications at the UK Intellectual Property Office (UKIPO) for drugs to treat breast cancer, colorectal cancer, prostate cancer, lung cancer and brain cancer.